Drug Trial Radar · NCT03017872
Dolutegravir and Darunavir Evaluation in Adults Failing Therapy
Last checked: Nov 19, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
831
Actual
Start
Nov 23, 2017
Primary completion
Nov 11, 2022
Study completion Oct 31, 2023
Sponsor
- Lead sponsor
- Kirby InstituteGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- UNITAID; National Institute of Allergy and Infectious Diseases (NIAID); National Health and Medical Research Council, Australia; ViiV Healthcare; Janssen Pharmaceutica
- First posted
- Jan 11, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
D²EFT is a randomised, open-label study in HIV-1 infected patients failing first-line antiretroviral therapy (ART). The study compares 2 regimens of second-line ART (dolutegravir and darunavir pharmaco-enhanced with ritonavir and dolutegravir and 2 prespecified NRTIs) with the WHO recommended regimen of 2NRTIs plus a ritonavir-boosted PI (Standard of Care (SOC)). 1,010 participants from 14 predominantly low-middle income countries will be followed for 96 weeks with the primary endpoint at week 48. The design is based on the hypothesis that one or both of the new regimens will be non-inferior to SOC in terms of virologic control while being easier to take, economically viable and affording simplification of treatment programs.
Conditions
- HIV Infections
Interventions
NRTIsDrug
In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection. In D2N arm, NRTIs are predetermined.
DolutegravirDrug
50mg tablet by mouth once daily for 96 weeks.
DarunavirDrug
800mg tablet by mouth once daily for 96 weeks.
RitonavirDrug
100mg tablet by mouth once daily for 96 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of participants in each arm whose plasma viral load is <50 copies/mL at 48 weeks by intention to treat.Time frame: At 48 weeks
Locations
28 sites in 14 countries. Site status is shown where the registry gives one.
Hospital Interzonal de Agudos San Juan de Dios
La Plata, Argentina
Hospital Dr Diego Paroissien
Isidro Casanova, Buenos Aires, Argentina
Hospital G de Agudos JM Ramos Mejia
Buenos Aires, Buenos Aires F.D., Argentina
CAICI
Rosario, Santa Fe Province, Argentina
Laboratório de Pesquisa Clinica Em Hiv/Aids - Instituto Nacional de Infectologia - Fiocruz
Rio de Janeiro, Brazil
Hospital San Borja-Arriaran
Santiago, Chile
ASISTENCIA Cientifica De Alta Complejidad S.A.S.
Bogotá, Colombia
Centre de traitementambulatoire de Donka ( Hopital de jour)
Conakry, Guinea
CART CRS, VHS Hospital
Chennai, Tamil Nadu, India
Dr. Cipto Mangunkusumo Hospital
Jakarta, Indonesia
RSUP Dr. Wahidin Sudirohusodo
Makassar, Indonesia
Dr. Soetomo Hospital
Surabaya, Indonesia
Dr Sardjito Hospital
Yogyakarta, Indonesia
University of Malaya Medical Centre
Kuala Lumpur, Malaysia
Hospital Pulau Pinang
George Town, Pulau Pinang, Malaysia
University of Sciences, Techniques and Technologies of Mali, University Clinical Research Center (UCRC)
Bamako, Mali
Instituto Nacional de Ciencias Medicas y Nutriciòn Salvador Zubiran
Mexico City, Mexico
Morales Vargas Centro de Investigacion SC
León, Guanajuato, Mexico
Hospital Civil de Guadalajara
Guadalajara, Jalisco, Mexico
Institute of Human Virology, Nigeria (IHVN)
Abuja, Nigeria
Desmond Tutu HIV Foundation
Cape Town, South Africa
Clinical HIV Research Unit (CHRU), Wits Health Consotium (Pty) Ltd
Johannesburg, South Africa
Perinatal HIV Research Unit (PHRU), Chris Hani Baragwanath Hospital
Soweto, South Africa
HIV-NAT (The HIV Netherlands Australia Thailand Research Collaboration), Thai Red Cross AIDS Research Centre
Bangkok, Thailand
Chiangrai Prachanukroh Hospital
Chiang Rai, Thailand
Srinagarind Hospital, Khon Kaen University
Khon Kaen, Thailand
Bamrasnaradura Infectious Diseases Institute
Nonthaburi, Thailand
University of Zimbabwe Clinical Research Centre
Harare, Zimbabwe
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.